The 100,000 probably was a sell and the 30k,10k and 60k were actually buys (put on LSE as sales). I bought some! They are still looking for right deal and unlike AIM there appears to be no time limit on Aquis. Email on the co website.
Agreed but short term weakness may be based on broker downgrade. finnCap target from 47 to 44p but eps 2021 downgraded from 0.6p to -0.2p and only 0.5p for 2022. They used EV/Sales for target hence 33p+9p for demergers+2p for cash, however this valuation method is usually used for valuing cos cheapness/dearness if corporate activity is likely. Meanwhile on assumed 20x PE for 2022 say, gives a price for core of 10p +9p+2p =21p short term. So contract news and Nasdaq listing news and non-core news is key to a rally, IMO. Long term, if all keeps going to plan, the shares are good value though.
finnCap downgraded their valuation from 47 to 44p. They have negative eps for FY21 and on their forecast for FY 22 OO are on a PE of 52x. Not sure what justifies that rating but obviously the spin offs will add to the value within their valuation. Corporate activity is also an unknown. I await the presentation.
Deepjoy - surely 1.4p eps on a 20p SP gives PE of 14.3. If you did apply 30x PE as acceptible (Ricky) the SP would be 21p+10p+3p=34p (based on adding non-core value and cash value to core from FinnCap note). Revenue multiple valuations are only used for loss making cos that are growing rapidly but we are told this is profitable.
The only announcement from the BoD will be ADMINISTRATION due to the losses after the failed RTO. Iclaprim is held elsewhere now and administration would end any potential value to Motif shareholders. Gold wants an end to this situation and will retain his reputation by blaming shareholders for voting down his wonderful RTO. Any other outcome can only be achieved by joining the SHAREHOLDERS group to have your say and a vote.
I have at last seen FinCap note. If I apply 20PE to 0.6adj eps forecast (Dec 21) I get 12p OO core (cf 34p Fincap unexplained) + 10p non-core + 3p cash (their figures) = 25p. Should the eps come in 1.2p say we get 37p (FinCap 47p). Also the value of the floats could be different. Trouble is the full results aren't out until June 2022. Of course we do not know the growth rate of the core going forward other than it may be an income stock with possibly high teens growth (?) following the recovery from losses. The next news is a presentation Q&A ON 9th Aug on Investor Dashboard. Maybe Vox too and more contracts (?) Then DIM possibly demerger early September, which will hopefully attract some Institutions. The interims are also due in Sept. Short term there is obviously a large seller or two depressing the price. I would be interested to know the top ten holdings now, as a list I got off Marketscreener.com has Acacia Research as the largest holder at 5.76% and Cathal at 3.21% so clearly out of date but there are a half dozen institutions on the list.
You can carry on being negative on a share chat site where possibly half the people aren't even shareholders. Then the very likely outcome is the company goes into administration and the end of Iclaprim proceeds (if any). Or you could join the many in the Shareholder Action Group who have all had to prove they are shareholders and with decent leadership. Your choice!
To find out what is happening:- "Please join by sending confirmation of your shareholdings screenshots and email… Alanclarke1000@hotmail.com You will be then be linked to the Telegram shareholders action group."
There is a persistant seller (TR?). Has anyone seen a stockbroker forecast for eps this year for OO? We could then get some idea of the true value and add on the spin-off values to get the real SP. At the moment it is guesswork.